Concord Biotech shares gain 5% after bagging USFDA approval for $500 million drug

According to Concord Biotech, this development aligns directly with its long-term growth strategy, aimed at reinforcing its commercial footprint across both US and international markets.

Leave a Reply

Your email address will not be published. Required fields are marked *